

The Global Prevalence of Hepatitis A Virus Infection and Susceptibility: A Systematic Review

Immunization, Vaccines and Biologicals



**World Health
Organization**

The Global Prevalence of Hepatitis A Virus Infection and Susceptibility: A Systematic Review

Immunization, Vaccines and Biologicals



**World Health
Organization**

**The Department of Immunization, Vaccines and Biologicals
thanks the donors whose unspecified financial support
has made the production of this document possible.**

This publication was produced under a contract with the
Expanded Programme on Immunization (EPI)
in the Department of Immunization, Vaccines and Biologicals, WHO, by:

Kathryn H. Jacobsen, PhD, MPH
George Mason University, Fairfax, Virginia, USA

Ordering code: WHO/IVB/10.01
Printed: June 2009

This publication is available on the Internet at:
www.who.int/vaccines-documents/

**Copies of this document as well as additional materials on
immunization, vaccines and biologicals may be requested from:**

World Health Organization
Department of Immunization, Vaccines and Biologicals
CH-1211 Geneva 27, Switzerland

• *Fax:* + 41 22 791 4227 • *Email:* vaccines@who.int •

© World Health Organization 2010

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

Printed by the WHO Document Production Services, Geneva, Switzerland

Acknowledgements:

The author is grateful to Andrea J. Bankoski and the Interlibrary Loan & Document Delivery staff of George Mason University for their able and dedicated assistance with this project.

The work was completed under a contract with the Expanded Programme on Immunization (EPI) in the Department of Immunization, Vaccines and Biologicals (IVB) of the the World Health Organization.

Suggested reference: Jacobsen KH. The global prevalence of hepatitis A virus infection and susceptibility: a systematic review. Geneva, Switzerland: World Health Organization; 2009.

TABLE OF CONTENTS

Background	5
Systematic Review Methods.....	8
Graph Interpretation.....	20
Summary of Findings by Region, Age, and Sex	26
Asia Pacific, High Income	31
Asia, Central	43
Asia, East	47
Asia, South	61
Asia, Southeast.....	72
Australasia.....	86
Caribbean	91
Europe, Central	96
Europe, Eastern.....	106
Europe, Western	112
Latin America, Andean.....	161
Latin America, Central.....	165
Latin America, Southern	171
Latin America, Tropical	178
North Africa / Middle East	188
North America, High Income	205
Oceania	215
Sub-Saharan Africa, Central	219
Sub-Saharan Africa, East	222
Sub-Saharan Africa, Southern.....	227
Sub-Saharan Africa, West	233
Appendix: Abstracts.....	238
Abstracts from High Income Asia Pacific	239
Abstracts from Central Asia	248
Abstracts from East Asia	251
Abstracts from South Asia	263
Abstracts from Southeast Asia.....	273
Abstracts from Australasia.....	284
Abstracts from the Caribbean.....	287
Abstracts from Central Europe	290
Abstracts from Eastern Europe.....	299
Abstracts from Western Europe	304
Abstracts from Andean Latin America.....	361
Abstracts from Central Latin America.....	363
Abstracts from Southern Latin America	368

Abstracts from Tropical Latin America	374
Abstracts from North Africa / Middle East	386
Abstracts from High Income North America	404
Abstracts from Oceania	416
Abstracts from Central Sub-Saharan Africa	417
Abstracts from East Sub-Saharan Africa	418
Abstracts from Southern Sub-Saharan Africa	423
Abstracts from West Sub-Saharan Africa	426

BACKGROUND

HEPATITIS A VIRUS

Hepatitis A virus (HAV) is a member of the *Hepatovirus* genus of the family *Picornaviridae*, and is a nonenveloped single-stranded RNA virus [Cuthbert, 2001; Koff, 1998]. HAV replicates in hepatocytes (liver cells) and interferes with liver function, sparking an immune response that causes liver inflammation. Four of the seven genotypes of HAV affect humans (genotypes I and III are the most common), but only one serotype exists. Infection with any of the genotypes usually results in lifelong immunity against all strains of hepatitis A virus.

TRANSMISSION

HAV is transmitted via the fecal-oral route either by direct contact with an infectious person or by ingestion of contaminated food or water. (Persons with hepatitis A can shed the virus in their stool beginning several weeks before the onset of symptoms. The viral concentration in stool is highest in the prodromal phase. For those who develop symptoms, the viral concentration is usually very low by the time jaundice appears and undetectable before symptoms resolve.)

RISK FACTORS

Predictors of past or recent infection with hepatitis A virus include low household socioeconomic status (low income, wealth, and/or educational level), a larger household size and crowding, residence in a rural area, membership in certain ethnic groups, limited access to improved water sources, and limited access sanitation facilities [Jacobsen, 2004]. Several additional high-risk population groups have been identified, including those who travel or immigrate from a non-endemic region to an endemic region and those who work in certain high-risk occupations (such as some day-care employees) [Franco, 2003].

CLINICAL CHARACTERISTICS

Hepatitis A infection has four clinical phases, although these do not occur in all patients. The first stage is an incubation period of 15 to 50 days (mean 28 to 30 days). This stage is asymptomatic, but the infected person may be actively shedding the virus in the stool. The second stage is a pre-icteric period of several days to weeks that may precede the onset of jaundice. This prodromal period is characterized by nonspecific symptoms followed by gastrointestinal symptoms such as anorexia (loss of appetite), nausea, vomiting, abdominal pain, fatigue, malaise, and fever. Other symptoms at this stage may include myalgia (muscle pain), arthralgia (joint pain), cough, pharyngitis, constipation, diarrhea, pruritus (itchiness), and urticaria (hives). Dark urine caused by elevated bilirubin levels usually occurs prior the onset of jaundice. In the third stage, the characteristic yellowing of the skin and eyes of jaundice appear and most symptoms subside, although clinical signs such as hepatomegaly and hepatic tenderness are found in about half of patients. There is no treatment for HAV infection. Jaundice usually resolves within a few weeks. The final stage is a convalescent period during which the patient recovers.

AGE

The course of HAV infection varies by age. Young children with an acute hepatitis A viral infection are usually asymptomatic or non-specific and not diagnosed as hepatitis A because of the lack of jaundice. Adults with acute infections may have mild disease or may develop serious complications. (An estimated 80 to 95% of children less than 5 years old have asymptomatic infections, compared to 10 to 25% of adults [Hollinger, 1996].) The risk of disease increases with age.

COMPLICATIONS

The vast majority of hepatitis A patients make a full recovery, and the case fatality rate is low. The estimated mortality rate is 0.1% for children less than 15 years old, 0.3% for adults ages 15 to 39, and 2.1% for adults ages 40 and old [Hollinger, 1996]. Several complications may occur. About 15% of patients experience prolonged jaundice and/or relapses over several months. Some develop cholestatic hepatitis, in which the bile duct leading from the liver to the intestine becomes blocked. A few suffer from fulminant (acute) liver failure that may require a transplant or cause death. Although liver failure is more likely to occur in patients suffering from chronic liver disease prior to the onset of hepatitis A, it can occur in anyone with HAV infection. Hepatitis A does not cause chronic liver disease.

COST

The low mortality associated with hepatitis A does not mean that disease is not severe: infection may require several days or weeks of hospitalization and may cause absenteeism from work or school for several weeks or months. Thus, infection can be expensive in terms of both direct medical costs and lost productivity.

SEROLOGY

Current or recent infection can be determined by the presence of anti-HAV IgM antibodies in serum, which are detectable soon after infection and can remain detectable for about 6 months (or longer, in some cases). Past infection can be determined by the presence of anti-HAV IgG antibodies in serum, which appear shortly after the onset of symptoms and confer long-term (usually lifelong) immunity. In this report, the prevalence of anti-HAV antibodies in serologic (blood) samples taken from population-based samples will be the primary measure of population seroprevalence rates. (These assays measure total anti-HAV and assume that IgM anti-HAV, found only in those with recent infection, is rare and as a result IgG anti-HAV is the only contributor to the total anti-HAV.) The laboratory

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_29229

